ProCE Banner Activity

APHINITY: Adjuvant Pertuzumab + Trastuzumab and Chemotherapy in HER2+ EBC

Slideset Download
Conference Coverage
Pertuzumab addition significantly reduced risk of recurrence vs current standard.

Released: June 05, 2017

Expiration: June 04, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology